Live Breaking News & Updates on Ridgeback capital

Stay informed with the latest breaking news from Ridgeback capital on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ridgeback capital and stay connected to the pulse of your community

Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform

- Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad

Boston , Massachusetts , United-states , Paris , France-general- , France , United-kingdom , London , City-of , British , Eleanor-perkin , Frazer-hall

Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform

/PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical...

Boston , Massachusetts , United-states , Paris , France-general- , France , United-kingdom , London , City-of , British , Eleanor-perkin , Frazer-hall

Quell Therapeutics Raises $156M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Boston , Massachusetts , United-states , United-kingdom , London , City-of , British , Houman-ashrafian , Iain-mcgill , Rachel-mears , Sv-health-investors , Therapeutics-ltd

Seattle startup TwinStrand raises $50M to expand tech that identifies rare genetic mutants

Seattle startup TwinStrand raises $50M to expand tech that identifies rare genetic mutants
May 5, 2021 at 10:55 am
Jesse Salk, CEO and co-founder of TwinStrand Biosciences. (TwinStrand Photo)
New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million in a Series B round led by Section 32, a California-based fund focused on biotech, technology, healthcare and life sciences. Total venture capital funding is now north of $70 million for the 6-year-old company.
Double strands of innovation: TwinStrand, which spun out of the University of Washington, has developed technology in both gene sequencing and analyzing sequencing results to help it find what the company calls “genetic needles in the haystack.”

California , United-states , Alexandria , Al-iskandariyah , Egypt , Jesse-salk , Michael-pellini , Jonas-salk , Twinstrand-biosciences , Foundation-medicine , Takeda-pharmaceuticals , University-of-washington

Ikena Oncology and Senti Biosciences Each Raise Series B Rounds

Ikena Oncology and Senti Biosciences Each Raise Series B Rounds
Posted on 01/07/2021
Ikena Oncology, Inc. is a clinical-stage biotechnology company that seeks to discover and develop patient-directed, biomarker-driven cancer therapies. Ikena Oncology announced the closing of US$ 120 million in a Series B financing round. The round was led and syndicated by Omega Funds and included participation from additional new investors: Fidelity Management & Research Company, LLC, Surveyor Capital (a Citadel company), Invus, Farallon Capital Management, BVF Partners, L.P., Cowen Healthcare Investments, Logos Capital, and HealthCor Management. Existing investors Atlas Venture, OrbiMed, and Bristol Myers Squibb all participated in the round. Ikena intends to use the proceeds from this financing to advance its pipeline of targeted oncology therapies, including its novel development candidate TEAD inhibitor IK-930, and a new first-in-class preclinical program targeting KRAS signaling.

China , Otello-stampacchia , Bayer-ag , Enterprise-associates , Atlas-venture , Fidelity-management-research-company , Bristol-myers-squibb , Ikena-oncology-inc , Ikena-oncology , Omega-funds , Fidelity-management , Research-company

Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-Generation Cell and Gene Therapies Using Advanced Gene Circuit Technology Platform

(2)
Senti Bio's gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas
Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma
Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round. The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Additional investors included Matrix Partners China, Mirae Asset Capital, Ridgeback Capital and Intel Capital as well as existing investors, including New Enterprise Associates (NEA), 8VC, Amgen Ventures and Lux Capital.

China , Alexandria , Al-iskandariyah , Egypt , Juergen-eckhardt , Curt-herberts , Tim-lu , Daniel-childs , Bayer-ag , Enterprise-associates , Linkedin , Senti-bio-gene-circuit-technology-platform

Bayer's VC arm leads $105M round for 'gene circuit' startup Senti Bio

(Getty Images)
Leaps by Bayer has led a chunky $105 million series B round for next-gen gene therapy player Senti Biosciences.
Nearly three years after its initial $53 million series A, Senti Bio now has now doubled its funding, adding Bayer’s VC arm into the mix and continuing in 2021 its ongoing mission to become a broad gene therapy player.
Fierce 15 winner Senti Bio’s approach involves what it calls “gene circuits,” essentially tweaking a cell’s genetic code which can morph in order to address the severity of a disease, all the while limiting side effects.
The Californian biotech is applying its gene circuit tech specifically toward allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, a growing area of interest in oncology.

China , California , United-states , Californian , Tim-lu , Enterprise-associates , Senti-bio , Clinical-trials-summit , Premier-educational-event-focused , Decentralized-clinical , Matrix-partners-china , Mirae-asset-capital

Leading $105M biotech funding, Bayer deepens cell therapy investment

Dive Brief:
Bayer's venture investment arm is leading a $105 million funding round in closely held Senti Biosciences, a California-based company using synthetic biology to develop off-the-shelf cell therapies for cancer. It is at least the third cell therapy company to receive investment from Bayer, which has since acquired one of those companies.
Senti is advancing two experimental treatments using "natural killer" immune cells to attack tumors in leukemia and liver cancer. The company believes its technology can create treatments with greater precision and control than current cell therapies.
The investment is another sign that Bayer believes the future of cancer cell therapies is in off-the shelf, or "allogeneic," approaches. Current cell therapies use patients' own T cells to treat blood cancers, an approach that requires a lengthy manufacturing process in order to re-engineer the cells to attack diseased cells.

China , California , United-states , Bluerock , Juergen-eckhardt , Novarti-kymriah , Enterprise-associates , Dive-brief , Senti-biosciences , Senti-bio , Bluerock-therapeutics , Matrix-partners-china

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
News provided by
Share this article
Share this article
VANCOUVER and HOUSTON, Dec. 15, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
"In 2020, ESSA made significant progress towards the development of EPI-7386, our highly-selective, oral, small molecule inhibitor that targets the N-terminal domain of the androgen receptor for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)," stated David Parkinson, MD, President and CEO of ESSA. "In July, we initiated a Phase 1 monotherapy dose escalation clinical study with EPI-7386 and the study is progressing as planned. Additionally, with the $48.9 million raised in a public offering in July, we believe we are well-positioned financially to advance the development of EPI-7386 in the current Phase 1 study as well as to initiate one or more combination studies with approved anti-androgen treatments."

Houston , Texas , United-states , Canada , Vancouver , British-columbia , David-parkinson , Pfizer-inc , Pharma-inc , Corporate-highlights , Fast-track-designation , Avidity-partners